AUTHOR INDEX

Aghakhani, S. *see* Larijani, B.
Akhondzadeh, S., Erfani, S., Mohammadi, M.R., Tehrani-Doost, M., Amini, H., Gudarzi, S.S. & Yasamy, M.T. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial, 145
Akhondzadeh, S. *see* Mohammadi, M.R.
Akrami, S.M. *see* Larijani, B.
Alexander, S.L. *see* Trujillo, J.M.
Al-Faleh, F.Z. *see* Matar, K.M.
Alla, F. *see* Baumann, M.
Al-Wazzan, A. *see* Matar, K.M.
Ameye, D. *see* Kayumba, P.C.
Amini, H. *see* Akhondzadeh, S.
Amir, J. *see* Romaino, S.M.N.
Asawamekin, A. *see* Poolsup, N.
Ashcroft, D.M. *see* Chen, L.-C.
Ashworth, M. *see* Parmentier, H.
Ayoola, E.A. *see* Matar, K.M.
Aziz, Z. Herbal medicines: predictors of recommendation by physicians, 241

Baker, D. *see* Hann, M.
Bargh, J. *see* Paterson, C.
Barton, R. *see* Goel, V.
Barutca, S. *see* Ceyhan, C.
Basu, T.K. *see* Goel, V.
Bauer, R. *see* Goel, V.
Baumann, M., Bonnetain, F., Briançon, S. & Alla, F. Quality of life and attitudes towards psychotropics and dependency: consumers vs. non-consumers aged 50 and over, 405
Bawazir, S.A. *see* Matar, K.M.
Bayrak, İ. *see* Ceyhan, C.
Beijnen, J.H. *see* de Maat, M.M.R.
Bek, S.J. *see* Hing, W.C.
Belitser, S.V. *see* Knoester, P.D.
Berdowska, A. *see* Żwirska-Korczala, K
Berke, S. *see* Francis, B.A.
Bernard, L. *see* Vuagnat, A.
Birkner, E. *see* Żwirska-Korczala, K
Blachon, M.-F. *see* Ciccolini, J.
Blackwood, L. *see* Stewart, D.
Blake, K. *see* Mehlhop, P.D.
Blanchfield, J.T. *see* Matthias, A.
Blauw, G.J. *see* Weverling-Rijnsburger, A.W.E.
Bleasel, M.D. *see* Boyles, P.J.
de Boer, A. *see* de Maat, M.M.R.
Bondareva, I.B., Jelliffe, R.W., Sokolov, A.V. & Tischenkova, I.F. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage, 105
Bonnetain, F. *see* Baumann, M.
Borras-Blasco, J. *see* Peris-Marti, J.F.
Boyles, P.J., Peterson, G.M., Bleasel, M.D. & Vial, J.H. Undertreatment of congestive heart failure in an Australian setting, 15
Briançon, S. *see* Baumann, M.
Britten, N. *see* Paterson, C.
Brown, D., Ford, J.L., Nunn, A.J. & Rowe, P.H. An assessment of dose-uniformity of samples delivered from paediatric oral droppers, 521

Caballero, J. & Nahata, M. Do statins slow down Alzheimer's disease? A review, 209
Calvert, M.J. & Freemantle, N. Use of health-related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health-related quality of life in clinical trials, 85
Cantrill, J. *see* Hann, M.
Carriere, K.C. *see* Johnson, D.
Cauza, E., Etemad, M., Winkler, F., Hanusch-Enserer, H., Partsch, G., Noske, H. & Dunky, A. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis, 431
Ceyhan, C., Meydan, N., Barutca, S., Tekten, T., Onbasılı, A.O., Ozturk, B., Unal, S. & Bayrak, İ. Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion, 267
Chanchareon, U. *see* Poolsup, N.
Chen, L.-C., Elliott, R.A. & Ashcroft, D.M. Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control, 215
Cheng, S.F., Hsu, H.-H., Lee, H.S., Lin, C.S., Chou, Y.C. & Tien, J.H. Rational pharmacotherapy in the diabetic hypertension: analysis-prescribing patterns in a general hospital in Taiwan, 547
Chinitz, D.P. *see* Kahan, N.R.
Chongsuvivatwong, V. *see* Janchawee, B.
Chou, Y.C. *see* Cheng, S.F.
Ciccolini, J., Mercier, C., Blachon, M.-F., Favre, R., Durand, A. & Lacarelle, B. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity, 307
Cottrell, N. *see* Millican, S.
Cox, A.R. & Langford, N.J. BANs to rINNS, 491
Cox, A.R., Marriott, J.F., Wilson, K.A. & Ferner, R.E. Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes, 31
Crowe, A.V. *see* Davies, J.

Davie, A. *see* Stewart, D.
Davies, J., Casey, J., Li, C., Crowe, A.V. & McClelland, P. Restoration of flow following haemodialysis catheter thrombus. Analysis of rt-PA infusion in tunnelled dialysis catheters, 517
De Voss, J.J. *see* Matthias, A.
Decaudin, B., Lemaitre, V., Gautier, S. & Urbina, M.-A. Epoetin in haemodialysis patients: impact of change from subcutaneous to intravenous routes of administration, 325
Deckers, C.L.P. *see* Knoester, P.D.
Dey, C.S. *see* Verma, N.K.
DiVall, M.V. *see* Trujillo, J.M.
Du, L.T. *see* Francis, B.A.
Dunky, A. *see* Cauza, E.
Duong, M. *see* Vuagnat, A.
Durand, A. *see* Ciccolini, J.

Egberts, A.C.G. *see* Knoester, P.D.
Eguchi, Y. *see* Konishi, H.
Ehrenhaus, M. *see* Francis, B.A.
Elliott, R.A. *see* Chen, L.-C.

© 2004 Blackwell Publishing Ltd

Erfani, S. *see* Akhondzadeh, S.
Eshraghian, R. *see* Larijani, B.
Etemad, M. *see* Cauza, E.

Favre, R. *see* Ciccolini, J.
Ferlazzo, B. *see* Minciullo, P.L.
Ferner, R.E. *see* Cox, A.R.
Ferner, R.E. *see* Langford, N.J.
Findlay, N. *see* Stewart, D.
Fitzmaurice, K.D. *see* Peterson, G.M.
Ford, J.L. *see* Brown, D.
Francis, B.A., Du, L.T., Berke, S., Ehrenhaus, M. & Minckler, D.S. Comparing the fixed combination dorzolamide–timolol (Cosopt®) to concomitant administration of 2% dorzolamide (Trusopt®) and 05% timolol – a randomized controlled trial and a replacement study, 375
Freemantle, N. *see* Calvert, M.J.
Fujii, M. *see* Konishi, H.
Fukumoto, K. *see* Takada, M.

Gan, S.H., Ismail, R., Wan Adnan, W.A., Zulmi, W. & Jelliffe, R.W. Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms, 455
Gandhi, P.J. *see* Silva, M.A.
Gangemi, S. *see* Minciullo, P.L.
Gasper, J. *see* MacLaren, R.
Gautier, S. *see* Decaudin, B.
Gharibdoost, F. *see* Larijani, B.
Giannetto, L. *see* Minciullo, P.L.
Gill, P. *see* Hann, M.
Goel, V., Lovlin, R., Barton, R., Lyon, M.R., Bauer, R., Lee, T.D.G. & Basu, T.K. Efficacy of a standardized echinacea preparation (Echinilin™) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial, 75
Golding, S. *see* Parmentier, H.
Gonyeau, M.J. *see* Trujillo, J.M.
González, L.R. *see* López, M.
Gonzalez-Delgado, M. *see* Peris-Marti, J.F.
van Gorp, E.C.M. *see* de Maat, M.M.R.
Green, B. *see* Millican, S.
Gribbin, M. *see* Scullin, C.
Gudarzi, S.S. *see* Akhondzadeh, S.

Hamed, A. *see* Ren, X.S.
Hann, M., Cantrill, J., Baker, D. & Gill, P. Prescribing patterns in high-need Health Authority populations: how does an ethnically mixed composition affect volume and cost?, 537
Hanusch-Enserer, H. *see* Cauza, E.
Heeley, E. *see* Layton, D.
Hekster, Y.A. *see* Knoester, P.D.
Hernández-Prats, C. *see* Llinares-Tello, F.
Herz, L. *see* Ren, X.S.
Hing, W.C., Bek, S.J., Lin, R.T.P. & Li, S.C. A retrospective drug utilization evaluation of vancomycin usage in paediatric patients, 359
Hoffmeyer, P. *see* Vuagnat, A.
Hsu, H.-H. *see* Cheng, S.F.
Huang, Y.-H. *see* Ren, X.S.
Huitema, A.D.R. *see* de Maat, M.M.R.

Iihara, N., Tsukamoto, T., Morita, S., Miyoshi, C., Takabatake, K. & Kurosaki, Y. Beliefs of chronically ill Japanese patients that lead to intentional non-adherence to medication, 417
Ijiri, Y., Hayahi, T., Ogihara, T., Ohi, K., Suzuki, K., Tamai, H., Kitaura, Y., Takenaka, H. & Tanaka, K. Increased digitalis-like immunoreactive substances in neonatal plasma measured using fluorescence polarization immunoassay, 565
Ishihara, H. *see* Rose, B.O.
Ismail, A.A. *see* Romaino, S.M.N.
Ismail, R. *see* Gan, S.H.
Ismail, R. *see* Romaino, S.M.N.
Ismail, R. *see* Teh, L.K.
Izadian, E.S. *see* Mohammadi, M.R.

Jędrzejowska-Szypułka, H. *see* Żwirska-Korczala, K
Jelliffe, R.W. *see* Bondareva, I.B.
Jelliffe, R.W. *see* Gan, S.H.
Jiao, Z., Shi, X.-J., Zhao, Z.-G. & Zhong, M.-K. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data, 247
Jin, Y. *see* Johnson, D.
Jochem, J. *see* Żwirska-Korczala, K
Johnson, D., Carriere, K.C., Jin, Y. & Marrie, T. Appropriate antibiotic utilization in seniors prior to hospitalization for community-acquired pneumonia is associated with decreased in-hospital mortality, 231
Johnson, R. *see* Ormiston, T.
Jung, R. *see* MacLaren, R.
Juroszek, L. *see* Stewart, D.

Kahan, E. *see* Kahan, N.R.
Kahan, N.R., Chinitz, D.P. & Kahan, E. Longer than recommended empiric antibiotic treatment of urinary tract infection in women: an avoidable waste of money, 59
Kahan, N.R., Chinitz, D.P., Waitman, D.A. & Kahan, E. Empiric treatment of uncomplicated UTI in women: wasting money when more is not better, 437
Kashani, L. *see* Mohammadi, M.R.
Kays, M.B. *see* Sowinski, K.M.
Kayumba, P.C., Risha, P.G., Shewiyo, D., Msami, A., Masuki, G., Ameye, D., Vergote, G., Ntawukuliryayo, J.D., Remon, J.P. & Vervaet, C. The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on *in vitro* dissolution, 331
Kazis, L.E. *see* Ren, X.S.
Kendall, M.J. *see* Langford, N.J.
Kendall, M.J. *see* Shehab, A.M.A.
Kendler, D.L. *see* Li, W.W.
Keyser, A. *see* Knoester, P.D.
Knoester, P.D., Belitser, S.V., Deckers, C.L.P., Keyser, A., Renier, W.O., Egberts, A.C.G. & Hekster, Y.A. Patterns of lamotrigine use in daily clinical practice during the first 5years after introduction in the Netherlands, 131
Koks, C.H.W. *see* de Maat, M.M.R.
Konishi, H., Eguchi, Y., Fujii, M., Saotome, T., Sasaki, T., Takahashi, K., Sudo, M., Morii, H., Minouchi, T. & Yamaji, A. Unusual hypersensitivity to warfarin in a critically ill patient, 485
Korzonek-Szlacheta, I. *see* Żwirska-Korczala, K
Kothari, J., Nash, M., Zaltzman, J. & Ramesh Prasad, G.V. Diltiazem use in tacrolimus-treated renal transplant recipients, 425
Krum, H. *see* Peterson, G.M.
Kuo, C.L., Wang, R.B., Shen, L.J., Lien, L.L. & Lien, E.J. G-protein coupled receptors: SAR analyses of neurotransmitters and antagonists, 279
Kurosaki, Y. *see* Iihara, N.

Lacarelle, B. *see* Ciccolini, J.
Landray, M. *see* Langford, N.J.
Lang, C.-S. *see* Matthias, A.
Langford, N.J., Landray, M., Martin, U., Kendall, M.J. & Ferner, R.E. Testing the practical aspects of therapeutics by objective structured clinical examination, 263
Langford, N.J. *see* Cox, A.R.

Larijani, B., Gharibdoost, F., Pajouhi, M., Sadjadi, A., Aghakhani, S., Eshraghian, R., Akrami, S.M. & Maalouf, G. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women, 1
Layton, D., Heeley, E. & Shakir, S.A.W. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data, 171
Lee, A.F. *see* Ren, X.S.
Lee, H.S. *see* Cheng, S.F.
Lee, T.D.G. *see* Goel, V.
Lehmann, R.P. *see* Matthias, A.
Lemaitre, V. *see* Decaudin, B.
Li, C. *see* Davies, J.
Li, S.C. *see* Hing, W.C.
Li, W.W. & Kendler, D.L. Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information, 531
Lien, E.J. *see* Kuo, C.L.
Lien, L.L. *see* Kuo, C.L.
Lin, C.S. *see* Cheng, S.F.
Lin, R.T.P. *see* Hing, W.C.
Llinares-Tello, F., Hernández-Prats, C., Munõz-Ruiz, C., Selva-Otaolaurruchi, J. & Ordovás-Baines, J.P. Monitoring trough plasma concentrations of mycophenolate mofetil in patients with uveitis, 53
Llyoyd, D.C.E.F. & Scrivener, G. Determinats of prescribing patterns for type II diabetes at Primary Care Trust level, 389
Lo, W. *see* Tallian, K.B.
López, M., González, L.R., Reyes, N., Sotolongo, J. & Pujol, V. Stabilization of a freeze-dried recombinant streptokinase formulation without serum albumin, 367
Lotthe, A. *see* Vuagnat, A.
Lovlin, R. *see* Goel, V.
Lyon, M.R. *see* Goel, V.

Maalouf, G. *see* Larijani, B.
de Maat, M.M.R., de Boer, A., Koks, C.H.W., Mulder, J.W., Meenhorst, P.L., van Gorp, E.C.M., Mairuhu, A.T.A., Huitema, A.D.R. & Beijnen, J.H. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care, 121
McCaig, D. *see* Stewart, D.
McCarthy, S. *see* Stewart, D.
McClelland, P. *see* Davies, J.
McElnay, J.C. *see* Scullin, C.
MacLaren, R., Gasper, J., Jung, R. & Vandivier, R.W. Use of exogenous erythropoietin in critically ill patients, 195
Mairuhu, A.T.A. *see* de Maat, M.M.R.
Manfredi, F. *see* Ormiston, T.
Marina, I. *see* Teh, L.K.
Marotta, G. *see* Minciullo, P.L.
Marrie, T. *see* Johnson, D.
Marriott, J.F. *see* Cox, A.R.
Martin, U. *see* Langford, N.J.
Masuki, G. *see* Kayumba, P.C.
Matar, K.M., Mayet, A.Y., Ayoola, E.A., Bawazir, S.A., Al-Faleh, F.Z. & Al-Wazzan, A. Isoniazid acetylation phenotyping in Saudi Arabs, 443
Matsuki, A. *see* Rose, B.O.
Matthias, A., Blanchfield, J.T., Penman, K.G., Toth, I., Lang, C.-S., De Voss, J.J. & Lehmann, R.P. Permeability studies of alkylamides and caffeic acid conjugates from echinacea using a Caco-2 cell monolayer model, 7
Mayet, A.Y. *see* Matar, K.M.
Meenhorst, P.L. *see* de Maat, M.M.R.
Mehlhop, P.D. & Blake, K. Impact of inadequately controlled asthma: a need for targeted therapy?, 189
Meinders, A.E. *see* Weverling-Rijnsburger, A.W.E.
Mercier, C. *see* Ciccolini, J.
Meydan, N. *see* Ceyhan, C.
Miller, D.R. *see* Ren, X.S.
Millican, S., Cottrell, N. & Green, B. Do risk factors for lactic acidosis influence dosing of metformin?, 449
Minciullo, P.L., Saija, A., Patafi, M., Giannetto, L., Marotta, G., Ferlazzo, B. & Gangemi, S. Vardenafil-induced generalized urticaria, 483
Minckler, D.S. *see* Francis, B.A.
Minouchi, T. *see* Konishi, H.
Miyoshi, C. *see* Iihara, N.
Mohammadi, M.R., Kashani, L., Akhondzadeh, S., Izadian, E.S. & Ohadinia, S. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial, 139
Mohammadi, M.R. *see* Akhondzadeh, S.
Morii, H. *see* Konishi, H.
Morita, S. *see* Iihara, N.
Msami, A. *see* Kayumba, P.C.
Mulder, J.W. *see* de Maat, M.M.R.
Munõz-Ruiz, C. *see* Llinares-Tello, F.

Nahata, M. *see* Caballero, J.
Nahata, M.C. *see* Tallian, K.B.
Nash, M. *see* Kothari, J.
Naunton, M. *see* Peterson, G.M.
Noor, A.R. *see* Romaino, S.M.N.
Noske, H. *see* Cauza, E.
Ntawukuliryayo, J.D. *see* Kayumba, P.C.
Nunn, A.J. *see* Brown, D.

Ohadinia, S. *see* Mohammadi, M.R.
Okawa, H. *see* Rose, B.O.
Onbasılı, A.O. *see* Ceyhan, C.
Ordovás-Baines, J.P. *see* Llinares-Tello, F.
Ormiston, T., Wolkowitz, O.M., Reus, V.I., Johnson, R. & Manfredi, F. Hormonal changes with cholesterol reduction: a double-blind pilot study, 71
Owatranporn, T. *see* Janchawee, B.
Ozturk, B. *see* Ceyhan, C.

Pajouhi, M. *see* Larijani, B.
Panning, B. *see* Rose, B.O.
Parmentier, H., Golding, S., Ashworth, M. & Rowland, G. Community pharmacy treatment of minor ailments in refugees, 465
Partsch, G. *see* Cauza, E.
Patafi, M. *see* Minciullo, P.L.
Paterson, C., Symons, L., Britten, N. & Bargh, J. Developing the Medication Change Questionnaire, 339
Penman, K.G. *see* Matthias, A.
Peris-Marti, J.F., Borras-Blasco, J., Rosique-Robles, J.D. & Gonzalez-Delgado, M. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation, 65
Peterson, G.M., Fitzmaurice, K.D., Naunton, M., Vial, J.H., Stewart, K. & Krum, H. Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy, 23
Peterson, G.M. *see* Boyles, P.J.
Piepenbrock, S. *see* Rose, B.O.
Polaniak, R. *see* Żwirska-Korczala, K
Poolsup, N., Suthisisang, C., Prathanturarug, S., Asawamekin, A. & Chanchareon, U. *Andrographis paniculata* in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials, 37

Prathanturarug, S. *see* Poolsup, N.
Pujol, V. *see* López, M.

Ramesh Prasad, G.V. *see* Kothari, J.
Ranson, M. & Wardell, S. Gefitinib, a novel, orally administered agent for the treatment of cancer, 95
Remon, J.P. *see* Kayumba, P.C.
Ren, X.S., Lee, A.F., Huang, Y.-H., Hamed, A., Herz, L., Miller, D.R. & Kazis, L.E. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia, 471
Renier, W.O. *see* Knoester, P.D.
Reus, V.I. *see* Ormiston, T.
Reyes, N. *see* López, M.
Risha, P.G. *see* Kayumba, P.C.
Romaino, S.M.N., Teh, L.K., Zilfalil, B.A., Thong, C.P., Ismail, A.A., Amir, J., Salleh, M.Z., Noor, A.R. & Ismail, R. A simple and rapid genotyping method for beta-2 receptor (β2 AR) gene using allele specific multiplex PCR, 47
Rose, B.O., Ishihara, H., Okawa, H., Panning, B., Piepenbrock, S. & Matsuki, A. Repeatability of measurements of the initial distribution volume of glucose in haemodynamically stable patients, 317
Rosemi, B.S. *see* Teh, L.K.
Rosique-Robles, J.D. *see* Peris-Marti, J.F.
Rowe, P.H. *see* Brown, D.
Rowland, G. *see* Parmentier, H.

Sadjadi, A. *see* Larijani, B.
Saija, A. *see* Minciullo, P.L.
Salleh, M.Z. *see* Romaino, S.M.N.
Saotome, T. *see* Konishi, H.
Sasaki, T. *see* Konishi, H.
Schuhmacher, H. *see* Vuagnat, A.
Scott, M.G. *see* Scullin, C.
Scrivener, G. *see* Llyoyd, D.C.E.F.
Scullin, C., Scott, M.G., Gribbin, M. & McElnay, J.C. A HRG-based costing model for estimating pharmacy costs associated with surgical procedures, 257
Selva-Otaolaurruchi, J. *see* Llinares-Tello, F.
Shakir, S.A.W. *see* Layton, D.
Shehab, A.M.A. & Kendall, M.J. Cardiac arrest: a role for vasopressin, 299
Shen, L.J. *see* Kuo, C.L.
Shewiyo, D. *see* Kayumba, P.C.
Shi, X.-J. *see* Jiao, Z.
Shibakawa, M. *see* Takada, M.
Silva, M.A. & Gandhi, P.J. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?, 497
Sitkiewicz, A. *see* Żwirska-Korczala, K.
Sokolov, A.V. *see* Bondareva, I.B.
Sotolongo, J. *see* López, M.
Sowinski, K.M. & Kays, M.B. Determination of ciprofloxacin concentrations in human serum and urine by HPLC with ultraviolet and fluorescence detection, 381
Stern, R. *see* Vuagnat, A.
Stewart, D., McCaig, D., Davie, A., Juroszek, L., Blackwood, L., Findlay, N. & McCarthy, S. Glucose self-monitoring in primary care: a survey of current practice, 273
Stewart, K. *see* Peterson, G.M.
Sudo, M. *see* Konishi, H.
Suthisisang, C. *see* Poolsup, N.
Symons, L. *see* Paterson, C.

Takabatake, K. *see* Iihara, N.
Takada, M., Fukumoto, K. & Shibakawa, M. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs, 183
Takahashi, K. *see* Konishi, H.
Tallian, K.B., Nahata, M.C., Lo, W. & Tsao, C.-Y. Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures, 511
Teh, L.K., Zilfalil, B.A., Marina, I., Rosemi, B.S. & Ismail, R. Genetic polymorphism of CYP2D6 in patients with cardiovascular disease – a cohort study, 559
Teh, L.K. *see* Romaino, S.M.N.
Tehrani-Doost, M. *see* Akhondzadeh, S.
Tekten, T. *see* Ceyhan, C.
Thong, C.P. *see* Romaino, S.M.N.
Tien, J.H. *see* Cheng, S.F.
Tischenkova, I.F. *see* Bondareva, I.B.
Toth, I. *see* Matthias, A.
Trujillo, J.M., Gonyeau, M.J., D.Vall, M.V. & Alexander, S.L. Spironolactone use in patients with heart failure, 165
Tsao, C.-Y. *see* Tallian, K.B.
Tsukamoto, T. *see* Iihara, N.

Unal, S. *see* Ceyhan, C.
Urbina, M.-A. *see* Decaudin, B.

Vandivier, R.W. *see* MacLaren, R.
Vergote, G. *see* Kayumba, P.C.
Verma, N.K. & Dey, C.S. RNA-mediated gene silencing: mechanisms and its therapeutic applications, 395
Vervaet, C. *see* Kayumba, P.C.
Vial, J.H. *see* Boyles, P.J.
Vial, J.H. *see* Peterson, G.M.
Vuagnat, A., Stern, R., Lotthe, A., Schuhmacher, H., Duong, M., Hoffmeyer, P. & Bernard, L. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion, 351

Waitman, D.A. *see* Kahan, N.R.
Wan Adnan, W.A. *see* Gan, S.H.
Wang, R.B. *see* Kuo, C.L.
Wardell, S. *see* Ranson, M.
Weverling-Rijnsburger, A.W.E., Blauw, G.J. & Meinders, A.E. Effect of atorvastatin on impaired vascular function in healthy old men, 157
Wilson, K.A. *see* Cox, A.R.
Winkler, F. *see* Cauza, E.
Wolkowitz, O.M. *see* Ormiston, T.
Wongpoowarak, W. *see* Janchawee, B.

Yamaji, A. *see* Konishi, H.
Yasamy, M.T. *see* Akhondzadeh, S.

Zaltzman, J. *see* Kothari, J.
Zhao, Z.-G. *see* Jiao, Z.
Zhong, M.-K. *see* Jiao, Z.
Zilfalil, B.A. *see* Romaino, S.M.N.
Zilfalil, B.A. *see* Teh, L.K.
Zulmi, W. *see* Gan, S.H.
Żwirska-Korczala, K., Berdowska, A., Jochem, J., Sitkiewicz, A., Birkner, E., Polaniak, R., Jędrzejowska-Szypułka, H. & Korzonek-Szlacheta, I. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders, 151

KEYWORD INDEX

Accuracy, 521
Acetylator, 443
Acetylcholine, 157
Administration route, 325
Adverse drug reaction, 483
Adverse drug reaction reporting, 31
Adverse events, 215
Albumin-free formulation, 367
Alendronate, 531
Alkylamides, 7
Allele frequency, 559
Alternative medicine, 339
Alzheimer's disease, 209
Aminoglycosides, 65
Anaemia, 195
Analgesic efficacy, 215
Andrographis paniculata, 37
Andrographolide, 37
Angiotensin converting enzyme inhibitors, 15
Antibiotics, 59, 231
Antihypertensive therapy, 425
Antimalarial drugs, 331
Antimicrobial drugs, 331
Aspirin, 183
Attention-deficit hyperactivity disorder, 139
Attitudes, 405
Atypical antipsychotics, 471
Autistic disorder, 145
Autoimmune, 53

Bayesian adaptive control, 105
β-blockers, 15
Beta2-adrenergic receptor (β_2 AR), 47
Bilirubin, 565
Bioavailability, 7
Bisphosphonate, 431, 531
Bone mineral density, 1, 431
Buffered formulation, 183

Caco-2 monolayers, 7
Caffeic acid conjugates, 7
Calcium channel blockers, 425
Carbamazepine 10, 247
Cardiotoxicity, 267
Cardiovascular disease, 559
Catheter, 517
Cholesterol, 23, 71, 157
Ciprofloxacin, 381
Clinical pharmacist, 121
Clinical pharmacology and therapeutics, 263
Colitis, 171
Combination therapy, 375
Common cold, 75
Community pharmacists, 465
Community-acquired pneumonia, 231
Compliance, 23, 417
Congestive heart failure, 15
Content homogeneity, 367
Continuous consumers, 405
Coronary heart disease, 537
Cost, 325
Cost forecasting, 257
Cost of treatment, 59
Critical care, 195
Critical illness, 485
CYP2D6 polymorphism, 559
Cyproheptadine, 145

Daily practice, 131
Dependency, 405
Diabetes, 273
Diabetes mellitus, 547
Digitalis-like immunoreactive substances, 565
Dihydropyrimidine dehydrogenase, 307
Diltiazem, 425
Dissolution, 331
Distribution volume, 317
Dopamine, 71
Dorzolamide, 375
Dose adjustment, 449
Dose uniformity, 521
Drug interaction, 425, 485
Drug interactions, 121
Drug quality, 331
Drug resistance, 359
Drug therapy, 15
Drug utilization, 339, 437, 547
Drug utilization review, 359
Duration of treatment, 59

Echinacea, 7
Education, 23
Effectiveness, 131
Electronic patient records, 437
Empiric antibiotic treatment, 437
Endothelial function, 157
Enteric-coated formulation, 183
Eptifibatide, 497
Epidermal growth factor receptor tyrosine kinase inhibitor, 95
Epilepsy, 105, 511
Epoetin, 325
11-Epoxide, 247
Erythropoietin, 195
Essential drugs, 331
Ethnicity, 389, 537
Etidronate, 531
Evidence-based practice, 273

Fluorescence polarization immunoassay, 565
Fluorescence detection, 381
Fluorouracil, 267
5-Fluorouracil, 307
Freeze-dried, 367

Gabapentin, 511
Gastrointestinal complications, 183
Gefitinib, 95
Gene silencing, 395
Gene therapeutics, 395
Genetic polymorphism, 47
Glaucoma, 375
Glucose, 273, 317
Glycaemic control, 273
Glycopeptide, 359
GP 11b/111a inhibitor, 497
G-protein coupled receptors, 279
Graves' disease, 151
Guidelines, 59, 437

Haemodialysis, 325, 517
Haloperidol, 145
Hashimoto's thyroiditis, 151
Health Authorities, 537
Health care resource groups, 257
Health service utilization, 231
Health-related quality of life, 85
Heart failure, 165
Hematocrit, 195
Hemoglobin, 195
Herbal medicine, 37
Herbal medicines, 241
HIV outpatients, 121
HMG-CoA reductase inhibitors, 209
Homovanillic acid, 71
HPLC, 307
5-HT, 145
5-Hydroxytryptamine, 157
Hypersensitivity, 485
Hypertension, 547
Hypertension control, 425

Immunosuppressive drugs, 425
Individualizing dosage regimen, 105
Infusion therapy, 351

© 2004 Blackwell Publishing Ltd

Initiation, 471
Intentional non-adherence, 417
International normalized ratio, 485
Intervention, 121
Iressa, 95
Isoniazid, 443

Lactic acidosis, 449
Lamotrigine, 131
Levothyroxine, 1
Lipid-lowering drug therapy, 23
Low-dose aspirin therapy, 183

Malaysian, 559
Medical education, 263
Medication diary, 339
Meta-analysis, 215
Metabolism, 95
Metformin, 449
Methicillin-resistant *Staphylococcus aureus*, 351
Methylphenidate, 139
Microparticle enzyme immunoassay, 565
Minor ailment schemes, 465
Missing data, 85
Monitoring, 23
Multiplexes PCR, 47
Multivariate regression, 389
Mycophenolate mofetil, 53
Mycophenolic acid, 53

Needs assessment, 537
Neonate, 565
Neurontin, 511
Neurotransmitter agonists and antagonists, 279
Non-linear mixed effect model, 247
Non-parametric expectation maximization, 455
"Non-st segment elevation myocardial infarction", 497
Non-small-cell lung cancer, 95

Objective structured clinical examination, 263
Occasional consumers, 405
Once-daily dose, 65
Osteomyelitis, 351
Osteoporosis, 431, 531
Outcome assessment, 339
Outcomes, 23

P dispersion, 267
Paediatric, 511
Paediatric oral droppers, 521
Pamidronate, 431
Patient characteristics, 471
Patient-centered care, 417
Patients' beliefs, 417
Pharmaceutical care, 531
Pharmaceutical costs, 257
Pharmacoeconomics, 437
Pharmacoepidemiology, 131
Pharmacokinetics, 95, 307, 317, 511
Pharmacovigilance, 171
Phenotype, 443
Plasma, 317
Population modeling, 105
Population pharmacokinetic modelling, 455
Population pharmacokinetics, 247
Postmenopausal, 431
Post-operative pain management, 215
Precision, 521
Predictors, 241
Premenopausal women, 1
Prescribing, 537
Prescribing practices, 449
Prescription analysis, 547
Prescription appropriateness, 59
Prescription drugs, 417
Prescription patterns, 131
Protocol, 85
Psychotropic drugs, 405

Quality of life, 405
Questionnaire survey, 273
Questionnaires, 339

Randomized controlled trial, 75, 85
Recommendation, 241
Refugee health care, 465
Regimen, 105
Repeatability, 317
Retention time, 131
Risedronate, 531
Risk factors, 449
RNAi, 395
Rofecoxib, 171
Rt-PA, 517

Safety, 425
SAR, 279
Saudi Arabs, 443
Schizophrenia, 471
Selective COX-2 inhibitor, 215
Self-monitoring, 273
Serotonin, 71
Signal generation, 171
SiRNA, 395
Sodium nitroprusside, 157
Soluble interleukin-2 receptor alpha, 151
Spironolactone, 15, 165
Stability, 331, 367
Standardized echinacea, 75
Statins, 157, 209
Streptokinase, 367
Suicide, 71
Suppressive therapy, 1
Surgery, 257
Systematic review, 37, 215

Theophylline, 139
Therapeutic drug monitoring, 53, 65, 105
Thiazolidinediones, 389
Timing, 85
Timolol, 375
Tirofiban, 497
Tobramycin, 65
Tramadol hydrochloride, 455
Transfusion, 195
Treatment, 165
Treatment outcome, 339
Trial, 431
Trough plasma concentration, 53
Type II diabetes, 389

Ultraviolet detection, 381
Uncomplicated urinary tract infection, 437
Undergraduate education, 31
Unstable angina, 497
Upper respiratory tract infection, 37
Uracil/dihydrouracil ratio, 307
Urinary tract infection, 59
Urticaria, 483
Uveitis, 53

Valproate pharmacokinetics, 105
Vancomycin, 351, 359
Vardenafil, 483
Very old, 157
Vitamin K deficiency, 485

Warfarin, 485

Yellow Card Scheme, 31